



#6

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boone et al.

Attorney Docket No. TLAB.79219

Serial No. 10/002,842

Filed: November 14, 2001

METHOD FOR DIFFERENTIATING
IRRITABLE BOWEL SYNDROME
FROM INFLAMMATORY BOWEL
DISEASE (IBD) AND FOR
MONITORING PERSONS WITH IBD
USING TOTAL ENDOGENOUS
LACTOFERRIN AS A MARKER

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service, postage prepaid, as First Class Mail in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, D.C. 20231, on:	
<u>4/22/02</u> Date	<u>Sandra Burns</u> Signature

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed herewith and listed on Form PTO-1449 (also enclosed) are photocopies of patents and/or documents which Applicant requests be considered by the Examiner and made of record.

U.S. Patent No. 5,124,252

Guerrant et al.

U.S. Patent No. 5,552,292

Uchida et al.

U.S. Patent No. 5,455,160

Fagerhol et al.

Trulove SC, Witts LJ. Cortisone in Ulcerative Colities. Final Report on a Therapeutic Trial. *British Medical Journal* 1955; 4947:1041-1048

Baveye, S., Ellass, E., Mazurier, J., Spik, G., Legrand, D. Lactoferrine: a Multifunctional Glycoprotein Involved in the Modulation of the Inflammatory Response. *Clin. Chem. Lab Med.* 1999; 37(3):281-86

Suleiman S, Sonnenberg A. Cost-effectiveness of Endoscopy in Irritable Bowel Syndrome. *Arch Intern Med* 2001; 161:369-75

Levay, PF and Viljoen, J. Lactoferrin: a General Review. *Haematologica.* 1995; 80(3):256-67

Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of Disease Activity in Ulcerative Colitis by Faecal Calprotectin, a Novel Granulocyte Marker Protein. *Digestion* 1997; 58:176-80

Lagerholm S., Dutta SK, Merchant, NB, Nair, PP. COX-2 Expression in Fecal Colonocytes from Patients with Inflammatory Bowel Disease. *Gastro* 2001; 120:A16

Hammer J., Talley NJ. Diagnostic Criteria for the Irritable Bowel Syndrome. *Am. J. Med.* 1999; 107:5S-11S

Limburg, P.L., Ahlquist, D.A., Sandborn, W., et al. Fecal Calprotectin Levels Predict Colorectal Inflammation among Patients with Chronic Diarrhea Referred for Colonoscopy. *Amer. J. of Gastro.* 2000; 95:2831-2837

Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal Lactoferrin, Interleukin-1 Beta, and Interleukin-8 Are Elevated in Patients with Severe *Clostridium Difficile* Colitis. *Clin Diagn Lab Immunol* 1997; 4:719-22

Naidu, A., Satyanarayan and Arnold R. 1997. Influence of Lactoferrin on Host-Microbe Interactions. In T. William Hutchens and Bo Lonnerdal (ed.), *Lactoferrin*, pp. 259-275. Humana Press

Andus T., Gross V., Caesar I., et al. PMN-elastase in Assessment of Patients with Inflammatory Bowel Disease. *Dig. Dis. Sci.* 1993; 35:97-105

Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate Markers of Intestinal Inflammation Are Predictive of Relapse in Patients with Inflammatory Bowel Disease. *Gastroenterology* 2000; 119:15-22

Dwarakanath, AD, Finnie, IA, Beesley, C M, et al. Differential Excretion of Leukocyte Granule Components in Inflammatory Bowel Disease: Implications for Pathogenesis. Clin. Sci. 1997; 92:307-313

Riley, L.W. 1995. Acute Inflammatory Diarrhea. In M. Blaser (ed.), P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant, Infections of the Gastrointestinal Tract. Raven Press, New York, NY

Tauxe, R., and M. Cohen. 1995. Epidemiology of Diarrheal Diseases in Developed Countries. In M. Blaser, P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant (ed.), Infections of the Gastrointestinal Tract. Raven Press, New York, NY

Sartor, R.B. 1995. Microbial Agents in Pathogenesis, Differential Diagnosis, and Complications of Inflammatory Bowel Disease. In M. Blaser, P. Smith, J. Ravdin, H. Greenberg, and R. Guerrant (ed.), Infections of the Gastrointestinal Tract. Raven Press, New York, NY

Mathias, JR, Clench, MH, Reeves-Darby, VG, et al. Effect of Leuprolide Acetate in Patients with Moderate to Severe Functional Bowel Disease: Double-Blind, Placebo-Controlled Study. Dig Dis Sci, 1994; 39(6):1155-62

Uchida, K., R. Matsuse, S. Tomita, K. Sugi, O. Saitoh, and S. Ohshiba. 1994. Immunochemical Detection of Human Lactoferrin in Feces as a New Marker for Inflammatory Gastrointestinal Disorders and Colon Cancer. Clin. Biochem. 27:259-264

Sugi, K., Saitoh, O., Hirata, I., and K. Katsu. 1996. Fecal Lactoferrin as a Marker for Disease Activity in Inflammatory Bowel Disease: Comparison with Other Neutrophil-derived Proteins. Amer. J. Gastroenterol. 91:927-934

Guerrant, R.L., V. Araujo, E. Soares, K. Kotloff, A. Lima, W. Cooper, and A. Lee. 1992. Measurement of Fecal Lactoferrin as a Marker of Fecal Leukocytes. J. Clin. Microbiol. 30:1238-1242

Fine, K.D., F. Ogunji, J. George, M. Niehause, and R. Guerrant. 1998. Utility of a Rapid Fecal Latex Agglutination Test Detecting the Neutrophil Protein, Lactoferrin, for Diagnosing Inflammatory Causes of Chronic Diarrhea. Amer. J. Gastroenterol. 93:1300-1305

Camilleri, M. 2001. Management of Irritable Bowel Syndrome. Gastroenterol. 120:652-668

Everhart, J.E. 1994. Digestive Diseases in the United States: Epidemiology and Impact., Inflammatory Bowel Diseases, pgs. 509-550 U.S. Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and

Digestive and Kidney Diseases. U.S. Government Printing Office, NIH Publication No. 94-1447

Everhart, J.E. 1994. Digestive Diseases in the United States: Epidemiology and Impact. , Irritable Bowel Syndrome, pgs. 595-612, U.S. Department of Health and Human Services, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Government Printing Office, NIH Publication No. 94-1447

Harris, J.C., H.L. DuPont, and B.R. Hornick. 1971. Fecal Leukocytes in Diarrheal Illness. Ann. Intern. Med. 76:697-703

Respectfully submitted,



Jean Dickman
Reg. No. 48,538

JD:sbx

SHOOK, HARDY & BACON L.L.P.
One Kansas City Place
1200 Main Street
Kansas City, Missouri 64105-2118
816/474-6550